Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Ottawa

www.uottawa.ca

Latest From University of Ottawa

Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs

An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.

Deals Financing

AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness

Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
Medical Device Clinical Trials

Thoratec's Bleeding Edge

The striking results of the REMATCH trial, demonstrating the efficacy of Thoratec's ventricular assist device to extend the life of terminal heart failure patients, is heartening clinicians and patients and opening up new markets for ventricular assist device manufacturers. Thoratec still faces FDA and reimbursement hurdles before its devices become long-term therapies in large volumes of patients. Meanwhile, the competition hopes to profit from the precedent-breaking REMATCH results, and overtake Thoratec's lead with claims of technological superiority in the long-term heart assist market.
Medical Device Business Strategies

Aegera Therapeutics Inc.

Aegera Therapeutics Inc. was formed in May 2000 through the merger of Apoptogen Inc. and Exogen Neurosciences Inc. Aegera will build on the neural signal transduction and apoptosis platforms of its founding companies with a goal of discovering and developing therapeutics for neurodegenerative diseases, peripheral neuropathies and cancer.
BioPharmaceutical
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register